🔴 Biovie is trading 5.37% down in after-hours trading after Phase 2 trial misses statistical significance

Biovie is trading at $1.94 (-5.37%) after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across all endpoints in the overall population.

• Significant findings appeared only in prespecified subgroups, which the company described as hypothesis-generating.
• BioVie entered an agreement allowing sales of up to $6,464,341 in stock, creating potential dilution.
• Management is scheduled to discuss the results on September 15, 2026, at 8:30 a.m. ET.